FDA APPROVES UROLIFT SYSTEM TO TREAT ENLARGED PROSTATE
The UroLift System by NeoTract Inc. has been approved by the U.S. Food and Drug Administration (FDA) as a minimally invasive device to relieve low or blocked urine flow in men ages 50 or older. The device works by pulling back the prostate tissue that is pressing on the urethra to improve urine flow. The UroLift system uses small implants that are placed to open the urethra directly by retracting the obstructing prostatic lobes without applying any incisions.
The company’s vision is said to be set on improving wellness and overall quality of life for people suffering from important urological conditions. The initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally-invasive device designed to treat lower urinary tract symptoms (LUTS).
BPH is a common condition afflicting more than 500 million aging men worldwide. More than half of men in their sixties have some urinary problems due to enlarged prostate, including frequent urination, weak stream, and leaking. Current treatment options include drug therapy and surgery to remove part of the prostate. The Urolift is implanted by a doctor using a handheld device that is inserted through the urethra. Potential side effects reported in company trials include pain during urination, blood in urine, and decreased urine flow.